Drug intelligence / Profile preview

Cyclosol

Development stage: Unknown
Lead developer: Novaliq
Administration: Ophthalmic

Overview

Cyclosol is the lead project of Novaliq, a German drug delivery company. It is an ophthalmic formulation that was being advanced through a Phase II proof-of-concept study. The development of Cyclosol was supported by financing rounds from dievini Hopp Bio Tech holding GmbH & Co. KG, the investment firm of SAP co-founder Dietmar Hopp. The capital was intended to ensure the company's liquidity and to progress Cyclosol and other ophthalmic formulations into clinical trials.

Targets

PPIA (Peptidyl-prolyl cis-trans isomerase A)CN (Calcineurin)

Beyond the preview

Go deeper on Cyclosol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclosol.

Explore the full profile